Follow us...


Search News Archives





View Channel

Laboratory Products



View Channel

Special Offers and Promotions


Microscopy | Image Analysis



View Channel

Separation Science



View Channel

Coronavirus (COVID-19)



View Channel

Research & Case Studies



View Channel

Conferences | Events

BIOHIT supplies COVID-19 detection kits in the UK

publication date: May 7, 2020
author/source: BIOHIT Healthcare Ltd


BIOHIT Healthcare Ltd is now distributing test kits for the diagnosis of both current and past COVID-19 infections to help in the fight against coronavirus in the UK.

The new product line includes the MutaPLEX® Coronavirus kit from Immundiagnostik AG (IDK) – a real-time RT-PCR assay to screen for infected individuals – and Epitope Diagnostics Inc's (EDI's) immunodiagnostic tests for IgM and IgGCOVID-19 antibodies, to detect past infections.

The IDK MutaPLEX coronavirus screening assay allows the detection of SARS-CoV-2 viral RNA in a variety of biological specimens, especially nasal/throat swabs. This real time RT-PCR kit contains all the reagents, primers and dual-labelled probes required for the amplification and simultaneous differentiation of RNA from SARS-CoV-2 and other betacoronaviruses, as well as house-keeping genes designed to prevent false negative results due to insufficient sample collection or transport problems.

EDI's Novel Coronavirus COVID-19 ELISA kits provide qualitative detection of antibodies in patientserum, indicating a past COVID-19 infection. The IgM assay provides the earliest immunodiagnosticindication of an infection, while the IgG test can be used to aid detection and provide an indication of long-term immunological response, making it particularly useful in cases where clustering is suspected or differential diagnosis is required.

These tests extend and complement BIOHIT's repertoire of diagnostic kits for gastroenterology, aiding the evaluation of patients with both GI and upper respiratory complaints, as COVID-19 may include stomach and bowel symptoms in some cases. Inflammatory bowel disease patients being treated with immunosuppressive agents should also be considered at high risk for COVID-19, making differential diagnosis essential.

Graham Johnson, Managing Director of BIOHIT Healthcare Ltd, commented: "Access to diagnostic testing is vital to coordinate an effective response to this global pandemic. By distributing these kits, we hope to streamline and simplify the UK supply chain, allowing more people to be tested sooner. This is just one piece of the puzzle, but it is important that we all do our small part in protecting both individuals and the NHS and, ultimately, saving lives."

About BIOHIT Healthcare Ltd

BIOHIT Healthcare Ltd is part of the Finnish public company, BIOHIT OYJ, which specialises in the development, manufacture and marketing of products and analysis systems for the early diagnosis and prevention of gastrointestinal diseases. The company's many unique and patented diagnostic tests transform clinical practice and make screening, diagnosis and monitoring of gastrointestinal diseases efficient and cost effective. Non-invasive diagnostics are at the core of BIOHIT's offering, making it the provider of choice for leading gastroenterologists and laboratory scientists worldwide.


Learn more about BIOHIT


Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin


Request your free copies HERE




Popular this Month

Top 10 most popular articles this month


Today's Picks




Looking for a Supplier?

Search by company or by product


Company Name:






Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


Media Partners